Kyverna Therapeutics

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Kyverna Therapeutics sits in the upper quartile of US sponsors by registered trial count (#2,085 of 15,742 sponsors by registered trial count).

6 total trials 2 currently recruiting early-phase tilt upper quartile by trial count

Kyverna Therapeutics: 6 sponsored US clinical trials, 2 recruiting.

Kyverna Therapeutics sponsors 6 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting. 0 of these trials are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Stiff Person Syndrome, with 2 trials.

Upper-quartile sponsor footprint

Kyverna Therapeutics sits in the upper quartile of the sponsor corpus (#2,085 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Open and recent trials

6 total, page 1 of 1

RECRUITING

A Long-Term Follow-Up Study for Participants Previously Treated With KYV-101

NCT07403188
RECRUITING Phase 2

KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis

NCT06193889
ACTIVE NOT RECRUITING Phase 2

KYSA-8: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Treatment Refractory Stiff Person Syndrome

NCT06588491
ACTIVE NOT RECRUITING Phase 2

KYSA-7: A Study of Anti-CD19 CAR T-Cell Therapy, in Subjects With Refractory Primary and Secondary Progressive Multiple Sclerosis

NCT06384976
ACTIVE NOT RECRUITING Phase 1

KYSA-5: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Systemic Sclerosis

NCT06400303
ACTIVE NOT RECRUITING Phase 1

KYSA-1: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis

NCT05938725

Phase Distribution

PhaseTrial count
Phase 1 2
Phase 2 3

Therapeutic Areas

Stiff Person Syndrome 2
Multiple Sclerosis 2
SPS 1
Systemic Sclerosis - 2013 ACR/EULAR Classification Criteria 1
Systemic Sclerosis - Diffuse Cutaneous 1
Refractory Lupus Nephritis 1
MS 1
Lupus Nephritis - World Health Organization (WHO) Class III 1
Lupus Nephritis - WHO Class IV 1
Systemic Sclerosis 1

What is open in the Kyverna Therapeutics pipeline

2 recruiting of 6 indexed (33% open).

Phase mix: 0 late (III/IV) vs 5 early (I/II) (early-phase heavy).

Top condition: Stiff Person Syndrome (2 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Kyverna Therapeutics: open-pipeline peers nationwide

Peers matched on 6 registered trials and 33% open enrollment, not the therapeutic-area sidebar.

Kyverna Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 246810 0%20%40%60%80% Total trials Recruiting share Kyverna Therapeutics23andMeAardvark TherapeuticsAbbisko Therapeutics CoAbGenomics B.V Taiwan BranchAadi BioscienceAaron CookAbivax S.A.Actuated Medical
Kyverna Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Kyverna Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 6 trials (± recruiting share)

Sponsors near 33% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Kyverna Therapeutics page

6 registered trials is a research-attention snapshot, not an endorsement of Kyverna Therapeutics or any single study.

  • 2 of Kyverna Therapeutics's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Stiff Person Syndrome is the condition Kyverna Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Stiff Person Syndrome trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Kyverna Therapeutics pipeline card: 6 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.